Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete
the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate
in this study. This study consists of 10 month treatment phase and 1-3 week tapering phase.
The 2 follow-up visits will be evaluated after 2 weeks and 4 weeks of last study medication
dosing.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.